Hong Kong's ORI hits first close on Fund II, exits Kymab
Hong Kong healthcare-focused VC firm ORI Capital has reached a first close of $112 million on its second fund and exited its largest investment, UK biotech developer Kymab, as part of a $1.1 billion deal.
A second close that would take Fund II past 50% of its $400 million target is currently being finalized, according to a source familiar with the situation. A third close is expected by the end of 2021....
More on Greater China
Latest News
Carlyle faces activist challenge to Japan Asia Group deal
An investment firm with ties to renowned Japanese activist investor Yoshiaki Murakami is challenging The Carlyle Group’s JPY37 ($355 million) bid for Japan Asia Group by launching a tender offer of its own.
Hong Kong regulation: Carry on
The proposal to place a 0% tax on carried interest has been welcomed in Hong Kong, but PE industry participants are quietly looking to Hong Kong Monetary Authority to ensure balanced execution of the policy
Fund focus: Oceanpine opens to external capital
Technology and healthcare-focused Oceanpine Capital sees the large GP commitment to its fund and the network of its founder as key differentiators in a competitive Chinese market
CPE, SDIC lead $46m round for China's Jaka Robotics
Chinese industrial robot manufacturer Jaka Robotics has raised RMB300m ($46m) in Series C funding led by CPE and State Development and Investment Corporation (SDIC).